Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Evernorth's announcement of the availability of a Humira biosimilar at $0 out of pocket for Accredo patients in June is set to save individual patients around $3,500 on average per year. The biosimilar will offer both high- and low-concentration options, providing cost-effective alternatives for patients.

Positive

• The availability of a Humira biosimilar at $0 out of pocket for Accredo patients is a significant cost-saving opportunity.
• Individual patients are estimated to save around $3,500 on average per year with the biosimilar option.
• The biosimilar will offer both high- and low-concentration interchangeable options, providing flexibility for patients' needs.
• This announcement showcases Evernorth's commitment to providing cost-effective healthcare solutions for patients.

Negative

• None.

• High- and low-concentration interchangeable biosimilar will be available, estimated to save individual patients around $3,500 on average per year 
• Biosimilar price will be about 85% lower than Humira^®*

BLOOMFIELD, Conn., April 25, 2024 /PRNewswire/ -- In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira^® biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy Accredo beginning this June. The high- and low-concentration interchangeable biosimilar will be produced for Evernorth's affiliate private label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with multiple manufacturers. It will be available at $0 out of pocket for most patients through Quallent's copay assistance program. This program is estimated to save individual patients around $3,500 on average per year.

"Biosimilars can help drive significant savings for patients and their health plans now and into the future. To help achieve those savings, it is important to make sure patients are supported and their experience is seamless," said Matt Perlberg, president of Evernorth Health Services' pharmacy and care delivery businesses. "Because of the leading capabilities we have within Evernorth and across the supply chain, we are uniquely positioned to make patients' experiences as simple as possible."

The biosimilar price will be about 85% lower than the list price for Humira^®. For many employers, unions, municipalities and other health plan sponsors that choose to work with Accredo as part of their specialty pharmacy network offering, this represents an opportunity for significant savings.

More than 100,000 Accredo patients currently use either Humira^® or one of its biosimilars, supported by specialty-trained pharmacists and nurses in Accredo's Therapeutic Resource Center for inflammatory conditions. Accredo's 15 condition-specific Therapeutic Resource Centers connect patients with pharmacists and nurses 24 hours a day, 7 days a week, helping to ensure patients receive care from clinicians who specialize in their condition and who take the time to understand their circumstances.

"Patients living with an inflammatory condition like Crohn's disease or rheumatoid arthritis are often navigating multiple medications prescribed by different physicians," said Susan Peppers, RPh, vice president of pharmacy practice at Evernorth. "Accredo helps them manage everything around their specialty medicine – from working with their physicians, counseling on their therapy, and administering their medications to coordinating copay assistance and working with the patient's health plan to secure coverage. Last year alone, we helped patients save nearly $2.8 billion by connecting them with copay assistance programs, and we look forward to helping patients save even more this year."

About Evernorth Health Services
Evernorth Health Services creates pharmacy, care and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at evernorth.com.

Media Contact
Justine Sessions
Justine.Sessions@evernorth.com
860-810-6523

*Humira® is a product of AbbVie.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-announces-humira-biosimilar-available-at-0-out-of-pocket-for-accredo-patients-in-june-302128023.html

SOURCE Evernorth Health Services

FAQ

What did Evernorth announce regarding Humira for Accredo patients?

Evernorth announced the availability of a Humira biosimilar at $0 out of pocket for Accredo patients in June.

How much can individual patients save on average per year with the Humira biosimilar?

Individual patients are estimated to save around $3,500 on average per year with the Humira biosimilar.

What options will the Humira biosimilar offer for patients?

The Humira biosimilar will offer both high- and low-concentration interchangeable options.

When will the Humira biosimilar be available for Accredo patients?

The Humira biosimilar will be available in June for Accredo patients.

What is the cost of the Humira biosimilar for Accredo patients?

The Humira biosimilar will be available at $0 out of pocket for Accredo patients.